Personalis (NASDAQ:PSNL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Personalis (NASDAQ:PSNL) from a sell rating to a hold rating in a research report released on Sunday.

PSNL has been the topic of several other research reports. Guggenheim upped their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Needham & Company LLC raised their price target on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Morgan Stanley cut their target price on Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Finally, BTIG Research lifted their target price on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Personalis has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Trading Up 1.8%

Personalis stock opened at $8.31 on Friday. Personalis has a 12 month low of $2.83 and a 12 month high of $11.50. The company has a market capitalization of $869.48 million, a price-to-earnings ratio of -9.13 and a beta of 2.02. The business’s fifty day simple moving average is $8.86 and its two-hundred day simple moving average is $8.19.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.05. The firm had revenue of $17.35 million during the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%. On average, equities research analysts predict that Personalis will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. boosted its holdings in Personalis by 273.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after purchasing an additional 7,896,714 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after buying an additional 1,347,439 shares during the last quarter. Kennedy Capital Management LLC lifted its holdings in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after buying an additional 1,281,695 shares during the period. Aberdeen Group plc lifted its holdings in shares of Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after buying an additional 861,948 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Personalis by 165.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock worth $8,960,000 after buying an additional 851,422 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.